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OBJECTIVE. The purpose of this study was to compare gadobenate dimeglumine–enhanced
MR angiography and unenhanced time-of-flight MR angiography for the detection of significant pe-
ripheral arterial occlusive disease using digital subtraction angiography as our reference standard.
SUBJECTS AND METHODS. Two hundred seventy-two patients underwent MR an-
giography and digital subtraction angiography of the iliofemoral arteries. MR angiography was
performed before (2D time-of-flight acquisitions) and after (spoiled gradient-echo acquisitions)
the administration of 0.1 mmol/kg of gadobenate dimeglumine at 1–2 mL/s. Contrast-enhanced
MR angiography and digital subtraction angiography of the calf arteries were performed in 241
of 272 participants. Images were evaluated on-site and by four blinded reviewers (three for MR
angiography, one for digital subtraction angiography). Comparative diagnostic performance for
the detection of significant (≥ 51% vessel lumen narrowing) disease was evaluated using the
McNemar test and generalized estimating equations. Interobserver agreement was assessed with
generalized kappa statistics. The chi-square test was used to compare technical failure rates.
RESULTS. Digital subtraction angiography confirmed significant disease (597 stenoses,
386 occlusions) in 983 iliofemoral segments. The sensitivity (54–80.9%), specificity
(89.7–95.3%), and accuracy (85–87.5%) of contrast-enhanced MR angiography for the detec-
tion of significant iliofemoral disease were significantly (p < 0.001, all reviewers) better than
those of time-of-flight MR angiography (33.2–62.8%, 74.3–88.9%, and 68–77.3%, respec-
tively). Similar diagnostic performance was obtained for the calf arteries. The technical failure
rate with contrast-enhanced MR angiography (2.5–3.4%) was similar to that of digital subtrac-
tion angiography (1.4%) and significantly (p < 0.001) lower than that of time-of-flight MR an-
giography (6.2–18.0%). Significantly better reproducibility (p < 0.001) was obtained with con-
trast-enhanced MR angiography (82% vs 65.2% agreement; κ = 0.66 vs 0.45).
CONCLUSION. Improved diagnostic performance and reproducibility are achievable with ga-
dobenate dimeglumine–enhanced MR angiography in patients with peripheral arterial occlusive disease.
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eripheral arterial occlusive dis-
ease of the lower extremities is a
prevalent disorder, causing a wide
spectrum of disturbances and
symptoms with substantial morbidity. Typical
manifestations include intermittent claudica-
tion, pain at rest, tissue loss, and gangrene [1].
In patients with symptoms suggestive of pe-
ripheral arterial occlusive disease, information
about the number and severity of vascular le-
sions is essential for planning appropriate revas-
cularization therapy. Traditionally, assessment
of peripheral arterial occlusive disease before
treatment has been performed with conven-
tional catheter angiography. However, conven-
tional angiography is a highly invasive proce-
dure that carries substantial risk to the patient
[2]. The advent of alternative minimally inva-
sive procedures such as MDCT angiography
(MDCTA) [3–6] and contrast-enhanced MR an-
giography (CE-MRA) [7–16] has markedly re-
duced the need for preoperative diagnostic cath-
eter angiography, effectively limiting its use to
patients undergoing interventional treatment.
Of the minimally invasive techniques avail-
able, CE-MRA has the advantage of not re-
quiring ionizing radiation or large volumes of
iodinated contrast material. Moreover, with
improvements in MRI hardware and sequence
design [17–20] that permit greater spatial res-
olution and faster image acquisition, CE-MRA
is increasingly considered the method of
choice for imaging large vascular territories
such as the peripheral runoff vessels. The ad-
vent of MR contrast agents with beneficial
properties for vascular imaging may further
improve the diagnostic impact of CE-MRA.
Gadobenate dimeglumine (MultiHance,
Bracco Imaging) is a gadolinium contrast agent
whose r1 relaxivity in blood is roughly two
times higher than the r1 values of conventional
gadolinium contrast agents at available mag-
netic field strengths up to 3 T [21, 22]. The in-
creased r1 relaxivity derives from weak and
transient interaction of the Gd-BOPTA con-
trast-effective chelate of gadobenate dimeglu-
mine with serum albumin [23] and results in
significantly better vascular contrast enhance-
ment and better vessel delineation than that
achieved with conventional gadolinium agents
at equivalent or higher doses [24–28]. In the
peripheral vasculature, a 0.1 mmol/kg dose of
gadobenate dimeglumine has been shown to
be superior to an equivalent dose of gadopen-
tetate dimeglumine in terms of diagnostic
image quality [27] and to permit better visu-
alization of the arterial vasculature, particu-
larly in the lower runoff territory [27, 28].
Previously, sensitivity and specificity values
of 94% and 89–93% have been reported for the
diagnostic accuracy of gadobenate dimeglu-
mine–enhanced MR angiography in patients
with peripheral arterial occlusive disease [28].
However, these values were obtained in a rela-
tively small single-center population of just 28
patients using a standard contrast agent volume
of 34 mL per patient. Our study was performed
in a much larger multinational, multicenter pa-
tient population using a standard gadobenate
dimeglumine dose per patient of 0.1 mmol/kg.
Values for sensitivity, specificity, and overall
diagnostic accuracy for the detection of signif-
icant (≥ 51%) stenoocclusive disease were de-
termined using digital subtraction angiography
as the reference standard and were compared
with values obtained using unenhanced 2D
time-of-flight MR angiography (TOF MRA).
Subjects and Methods
This was a phase III, multicenter, open-label trial
conducted at 26 investigational centers in Europe and
North and South America. The study was reviewed
and approved by the local institutional review board
or ethics committee of each of the participating cen-
ters in accordance with good clinical practice [29]
and was performed in adherence to the Declaration of
Helsinki [30] and subsequent amendments and clari-
fications. Written informed consent was obtained
from each patient before inclusion in the study.
Study Population
All patients were enrolled between May 2003
and November 2004. Men and women were eligi-
ble for enrollment if they were 18 years old or older
and had known or suspected peripheral arterial oc-
clusive disease in the iliofemoral arteries based on
clinical examination or sonographic findings. All
patients were required to undergo a conventional
digital subtraction angiography examination within
1–30 days before or after the CE-MRA examina-
tion and to exhibit no change in clinical symptoms
related to peripheral arterial occlusive disease be-
tween the two procedures. Patients were not per-
mitted to undergo any therapeutic intervention for
vascular disease between the MR angiography and
the digital subtraction angiography procedures or
any other surgical procedure within 24 hours after
the administration of gadobenate dimeglumine.
Patients with known allergies to one or more of
the study agent ingredients or a known history of hy-
persensitivity to metals, including gadolinium or io-
dinated contrast media, were ineligible for inclusion,
as were patients who received any other investiga-
tional agent within 30 days before the study or any
other contrast agent within 24 hours before or after
gadobenate dimeglumine administration. Similarly,
patients who suffered severe claustrophobia, had
class III or IV congestive heart failure according to
the American Heart Association classification [31],
or had a pacemaker, metallic cardiac valve, or metal-
lic vascular stent in one or more of the vessels of in-
terest were also ineligible for inclusion. Finally,
pregnant or lactating women were ineligible for in-
clusion, as were patients with any medical condition
or other circumstances that would significantly de-
crease the chances of obtaining reliable data or of
achieving study objectives. A total of 294 patients
with known or suspected peripheral arterial occlu-
sive disease based on clinical or sonographic find-
ings were enrolled. Of these 294 patients, 287 (207
men, 80 women; mean age, 65.7 ± 9.95 years; range,
40–93 years) underwent TOF MRA and CE-MRA.
MR Angiography
The 287 participants underwent MR angiogra-
phy at 1.5 T on commercially available MR scan-
ners equipped with a gradient of ≥ 20 mT/m. The
MR scanners used for the study were from Siemens
Medical Solutions (Symphony, n = 69 [24.0%]; So-
nata, n = 75 [26.1%]; Avanto, n = 12 [4.2%]), Phil-
ips Medical Systems (Gyroscan Intera, n = 69
[24.0%]), or GE Healthcare (Genesis Signa, n = 40
[13.9%]; Excite, n = 22 [7.7%]).
MR angiography was performed using a 2D TOF
MRA sequence before contrast agent administration
and a 3D spoiled gradient-echo MR angiography se-
quence immediately after administration of gadobenate
dimeglumine. The large number of investigating cen-
ters involved in the study and the wide variety of imag-
ing systems used resulted in necessarily slightly differ-
ent parameters among centers for the TOF MRA and
CE-MRA sequences. Nevertheless, each sequence at
each center was selected to meet minimal requirements
for image acquisition and interpretability.
The parameters for the TOF MRA sequence var-
ied among centers as follows: axial orientation;
TR/TE range, ≤ 60/4.2–7.2; flip angle, 30–70°; exci-
tations, 1–2; slice thickness, < 4 mm; matrix,
≥ 256 × 160; overall acquisition time, 5–12 minutes.
ECG gating was performed for 75% of the patients.
CE-MRA of the peripheral arteries was performed
with a dedicated phased-array peripheral coil (225
patients) or with a body coil (62 patients) and a bolus
chase technique using the following sequence param-
eters: coronal orientation; TR range/TE range,
2.3–6/0.78–2.15; flip angle, 25–45°; excitations,
0.5–1; slice thickness, 1–3.5 mm; matrix,
≥ 256 × 224; true in-plane spatial resolution,
0.68 × 0.68–1.3 × 1.3 mm; overall acquisition time,
≤ 50 seconds. The iliofemoral field of view for both
the TOF MRA and CE-MRA sequences was tailored
for each patient to include arterial vasculature from 2
cm above the aortic bifurcation to a point on the
popliteal artery at the level of the knee joint line. MR
P
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angiography of the calf arteries was optional at all in-
vestigational centers as a secondary acquisition after
full CE-MRA of the iliofemoral arteries.
The CE-MRA sequence was acquired after the
administration of gadobenate dimeglumine at a dose
of 0.1 mmol/kg of body weight. Contrast agent ad-
ministration was performed using a power injector at
a rate of 1–2 mL/s, followed by a 20-mL saline flush
at the same rate. Timing for the CE-MRA sequence
was achieved by means of a bolus timing acquisition
(n = 173 participants) or through the use of an auto-
matic or MR fluoroscopic bolus detection technique
(SmartPrep [GE Healthcare], BolusTrak [Philips
Medical Systems], or CARE Bolus [Siemens Medi-
cal Solutions], depending on the scanner manufac-
turer; n = 114 subjects). The test bolus timing ap-
proach involved acquisition of 45–60 dynamic
single-slice T1-weighted fast gradient-echo images
of the common femoral artery at a frequency of one
image per second after the administration of a 1- to
2-mL bolus of gadobenate dimeglumine.
Digital Subtraction Angiography
Conventional digital subtraction angiography was
performed by injecting an iodinated contrast medium
through a pigtail or straight 4- to 5-French catheter in-
serted via a femoral artery puncture using the
Seldinger technique. The catheter tip was positioned
in the abdominal aorta 5–10 cm above the aortic bi-
furcation. Anteroposterior, right anterior oblique, and
left anterior oblique projections at angulations of
15–30° were obtained of the aortoiliac station as ap-
propriate according to each center’s standard operat-
ing procedure. Anteroposterior projections were ob-
tained for the upper and lower leg stations. Most
digital subtraction angiography examinations were
performed using iodinated contrast media having io-
dine concentrations of > 200 mg I/mL (200–300 mg
I/mL in 58% of the subjects; > 300 mg I/mL in 42%
of the subjects). The total volume of contrast medium
administered was 50–200 mL. Individual injections
of 15–40 mL were administered at rates of 4–12 mL/s
depending on the vessel of interest.
Image Evaluation
Images were evaluated by on-site investigators
and by four off-site independent, experienced (at
least 10 years of experience in vascular imaging)
board-certified radiologists (three for MR angiogra-
phy, one for digital subtraction angiography) who
were not affiliated with any of the study sites and
who were fully blinded to all patient information and
to the results of other diagnostic procedures.
Off-site evaluation of digital MR angiography and
digital subtraction angiography images was per-
formed at an independent core imaging laboratory
equipped with two separate Windows (Microsoft)-
based workstations (AquariusNet Viewer, Tera-
Recon) for evaluation of images (two monitors) and
for recording of assessment findings using an elec-
tronic Case Report Form (e-CRF) system. All TOF
MRA and CE-MRA images were combined into a
single randomization pool, and each image set for
each patient was reviewed separately, one at a time
and in random order. In each case, axial source im-
ages and volumetric maximum-intensity-projection
(MIP) reconstructions were always displayed on the
two monitors set up for image evaluation. All routine
image review tools (window and level, zoom, pan,
and so forth) were available to the reviewers.
The three off-site reviewers of MR angiography
images performed their evaluations independently in
a fully blinded fashion. Evaluation of the iliofemoral
arterial anatomy from 2 cm above the aortic bifurca-
tion to the popliteal arteries at the level of the knee
joint was performed on a segmental basis in which
standard segments comprised the left and right com-
mon, internal, and external iliac arteries; the left and
right common, superficial, and deep femoral arteries;
and the left and right popliteal arteries.
Initial off-site evaluation was performed to deter-
mine the technical adequacy (quality of visualization)
of the TOF MRA and CE-MRA image sets. If any seg-
ment was not entirely in the field of view or was con-
sidered technically inadequate for any reason, no fur-
ther assessment was performed for that segment.
Assessment of all segments considered technically ad-
equate was then performed using a 3-point scale in
which 1 = stenosis of ≤ 50% (vessel with no clinically
significant disease), 2 = stenosis of 51–99% (vessel
with clinically significant disease), and 3 = occlusion
(vessel with 100% blockage of the vessel lumen).
Evaluation of calf vessels was performed using similar
assessment methodology with the calf vasculature di-
vided into segments comprising the left and right tib-
iofibular trunk, the left and right anterior and posterior
tibial arteries, and the left and right peroneal arteries.
The presence and location of collateral circulation
was assessed in a yes-or-no manner. Collateral circu-
lation was assigned to one of the following locations
per side (right and left): station 1 (from the abdominal
aorta to the external iliac artery), between stations 1
and 2 (from the abdominal aorta to the popliteal ar-
tery), station 2 (from the common femoral artery to
the popliteal artery), between stations 2 and 3 (from
the common femoral artery to the tibial arteries), and
station 3 and below (from the tibiofibular trunk to
downstream). Finally, the presence and type of asso-
ciated disease in each iliofemoral segment was re-
corded as none, aneurysm, dissection, or other.
Off-site evaluation of digital subtraction angiog-
raphy images was performed by a fourth indepen-
dent radiologist who had 12 years of experience in
angiographic procedures, was not affiliated with
the study centers, and was blinded to all clinical and
radiologic information. Digital subtraction angiog-
raphy images were combined into a second pool,
different from the MR angiography pool, for
blinded reviewing purposes, but were evaluated us-
ing similar assessment methodology and criteria.
On-site evaluation of MR angiography images
was performed using similar criteria to those of the
off-site evaluation. Evaluation of MR angiography
and digital subtraction angiography images was
performed independently by two experienced radi-
ologists (one for each technique) at each investiga-
tional site. Each reviewer was fully blinded to the
results of the other imaging technique.
Safety Evaluations
Physical examination was performed within 24
hours before gadobenate dimeglumine administra-
tion and at 24 hours after administration. Measure-
ment of vital signs (blood pressure, heart rate) was
performed within 24 hours before dosing and be-
fore the participant entered the magnet, and at 30
minutes, 1 hour, and 24 hours after gadobenate
dimeglumine administration. Recording of ECGs
was similarly performed before the patient entered
the bore of the magnet and at 1 hour and 24 hours
after administration of gadobenate dimeglumine.
In addition, blood and urine samples were collected
within 24 hours before gadobenate dimeglumine ad-
ministration and at 24 hours after administration. Lab-
oratory evaluation of collected samples was per-
formed for hematology (hematocrit, hemoglobin, and
counts of RBCs, WBCs, and platelets), blood chemis-
try (glucose, creatinine, total bilirubin, total protein, al-
bumin, aspartate aminotransferase, alanine ami-
notransferase, alkaline phosphatase, gamma glutamyl
transpeptidase, sodium, potassium, and chloride), and
urinalysis (protein, glucose, ketones, blood, and pH).
Finally, the safety of gadobenate dimeglumine
was assessed in terms of the incidence of adverse
clinical events from the time of signed informed con-
sent until 24 hours after gadobenate dimeglumine
administration. Adverse events were classified as se-
rious (i.e., death, life-threatening, or requiring or
prolonging hospitalization) or not serious (rated as
mild, moderate, or severe). The relationship of each
adverse event to the study agent was classified as
probable, possible, not related, unknown, or missing.
Statistical Analysis
The primary objectives were to determine the diag-
nostic accuracy of CE-MRA with gadobenate di-
meglumine for detection of significant stenoocclusive
disease (defined as stenosis of ≥ 51% or occlusion) of
the iliofemoral arteries using digital subtraction an-
giography as a reference standard, and to compare the
diagnostic performance of CE-MRA with that of un-
enhanced TOF MRA. Data from each of the three off-
site MR angiography reviewers and from the on-site
investigators were analyzed and presented separately.
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Sensitivity for detection of significant stenoocclu-
sive disease was defined as the number of correctly
identified significantly (≥ 51%) diseased segments on
TOF MRA or CE-MRA divided by the total number
of significantly (≥ 51%) diseased segments on digital
subtraction angiography. Specificity was defined as
the number of correctly identified segments in TOF
MRA or CE-MRA that were not diseased or not sig-
nificantly (< 51%) diseased divided by the total num-
ber of segments on digital subtraction angiography
that were not diseased or not significantly (< 51%)
diseased. Accuracy was defined as the number of cor-
rectly identified segments (either diseased or nondis-
eased) on MR angiography divided by the total num-
ber of segments evaluated on digital subtraction
angiography. All uninterpretable MR angiography im-
ages were considered inaccurate for all determinations
of diagnostic performance. If a segment was techni-
cally inadequate on MR angiography, this segment
was considered false-positive if the corresponding
digital subtraction angiography revealed a stenosis of
≤ 50%; however, this segment was considered false-
negative if the corresponding digital subtraction an-
giography revealed a stenosis of ≥ 51% or occlusion.
The sensitivity, specificity, and accuracy of TOF
MRA and CE-MRA were compared using the Mc-
Nemar test. In addition, supplemental supporting
analyses of sensitivity and specificity were per-
formed using generalized estimating equations
(GEEs) [32] to eliminate potential correlation-re-
lated bias caused by evaluation of multiple segments
for each patient. “Reviewer” was considered a fixed
effect in the GEE model.
Determinations of positive predictive value
(PPV), negative predictive value (NPV), positive
likelihood ratio, and negative likelihood ratio were
performed and compared descriptively for the two
MR angiography sequences. Determination of in-
terobserver agreement was evaluated by means of
the generalized kappa (κ) coefficient and by the
percentage of concordance among the three MR an-
giography reviewers.
The technical failure rate for each MR angiogra-
phy sequence was defined as the total number of
technically inadequate segments divided by the total
number of segments included in the field of view.
Comparison of the technical failure rate for TOF
MRA with that for CE-MRA for the iliofemoral ar-
teries was performed using the chi-square test.
A power calculation was performed on the basis
of the assumption that the expected difference in sen-
sitivity for detecting significant (≥ 51%) stenoocclu-
sive disease between TOF MRA and CE-MRA was
10%. Assuming that the proportion of discordant
pairs was 0.26 and that the sensitivity of TOF MRA
was 0.70, then for a two-sided 0.05 alpha level Mc-
Nemar test of equality of paired proportion, 225 par-
ticipants with at least one significant stenosis were
required for statistical power of 85%. Assuming a
10% dropout rate, at least 265 subjects were required
to enter the study. The total number of subjects as-
sessed for sensitivity was also sufficient for specific-
ity because each subject could have many negative
segments contributing to specificity.
All statistical analyses were performed using
the statistical software package SAS version 8.2
(SAS Institute).
Results
Of the 294 patients enrolled, 287 received
gadobenate dimeglumine at a dose of 0.1
mmol/kg of body weight and underwent
TOF MRA and CE-MRA. Each of these 287
patients was evaluated for safety and techni-
cal adequacy of the MR angiography exam-
inations. The remaining seven patients dis-
continued their study participation before
contrast agent administration.
Most patients (171/287, 59.6%) were 65
years old or older; the remainder were 40–64
years old. Most patients who received gado-
benate dimeglumine (165/287, 57.5%) pre-
sented with moderate to severe claudication
(stage IIb according to the classification of Fon-
taine et al. [33]). The remaining patients had
mild claudication (stage IIa; 53/287, 18.5%),
ischemic pain at rest (stage III; 38/287, 13.2%),
ulceration or gangrene (stage IV; 29/287,
10.1%), or were asymptomatic (2/287, 0.7%) at
presentation. Most participants underwent MR
angiography to confirm or evaluate a previ-
ously detected stenosis (131/287, 45.6%) or be-
cause of clinical symptoms suggestive of steno-
sis (117/287, 40.8%). A smaller proportion of
participants (39/287, 13.6%) underwent MR
angiography to guide revascularization or as
follow-up to a previous treatment.
Of the 287 participants to undergo MR an-
giography, only 272 (94.8%) also underwent
the required digital subtraction angiography
examination. Consequently, assessment of di-
agnostic performance was performed for 272
participants overall.
Technical Adequacy and Quality of 
Segment Visualization
The technical adequacy of TOF MRA and
CE-MRA for evaluation of the iliofemoral ar-
teries in all 287 participants who received gado-
benate dimeglumine is shown in Table 1. The
technical failure rate of CE-MRA for reviewers
1, 2, and 3 (2.8%, 2.5%, 3.4%, respectively)
was in all cases significantly (p < 0.001) lower
than the failure rate of TOF MRA (18.0%,
11.3%, 6.2%, respectively). Similar findings
were noted by the on-site investigators (6.6% of
iliofemoral segments were considered inade-
quate on CE-MRA compared with 32.2% on
TOF MRA; p < 0.001). Overall, the technical
failure rate of CE-MRA for the iliofemoral ar-
teries was low in absolute terms for each re-
viewer and comparable to the failure rate of
digital subtraction angiography (1.4%).
Off-site assessment of the calf arteries re-
vealed slightly greater numbers of technically
inadequate segments for both TOF MRA and
CE-MRA when compared with the iliofemoral
arteries (technical failure rate, 45.0%, 26.6%,
and 25.3% for TOF MRA compared with
12.0%, 8.2%, and 14.2% for CE-MRA rated by
reviewers 1, 2, and 3, respectively). However, a
similar trend for significantly (p < 0.001, all
TABLE 1: Technical Adequacy of TOF MRA and CE-MRA for Evaluation of Iliofemoral Arteries in 287 Patients
Adequacy
No. (%) of Segments
Reviewer 1 Reviewer 2 Reviewer 3 On-Site Reviewer
TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA
Total no. of segmentsa 4,138 4,261 4,086 4,220 4,058 4,240 4,276 4,276
Adequate 3,393 (82.0) 4,142 (97.2) 3,624 (88.7) 4,113 (97.5) 3,807 (93.8) 4,094 (96.6) 2,899 (67.8) 3,994 (93.4)
Inadequate 745 (18.0) 119 (2.8) 462 (11.3) 107 (2.5) 251 (6.2) 146 (3.4) 1,377 (32.2) 282 (6.6)
pb < 0.001 < 0.001 < 0.001 < 0.001
Note—TOF MRA = time-of-flight MR angiography, CE-MRA = contrast-enhanced MR angiography.
aIn field of view.
bChi-square test comparing TOF MRA and CE-MRA.
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reviewers) lower numbers of technically inade-
quate images on CE-MRA was apparent.
Moreover, the number of technically inade-
quate calf segments on CE-MRA was compa-
rable to the failure rate of digital subtraction
angiography (10.2%).
Diagnostic Performance
Iliofemoral arteries—Of the 272 partici-
pants to undergo both MR angiography and
digital subtraction angiography, only eight
(2.9%) did not have any iliofemoral segment
with significant (≥ 51%) stenoocclusive dis-
ease; the remaining 264 (97.1%) participants
had at least one iliofemoral segment with
significant disease. These 264 participants
comprised 14 (5.1%) who had one segment
with clinically significant disease, 29
(10.7%) who had two segments with clini-
cally significant disease, 43 (15.8%) who
had three segments with clinically signifi-
cant disease, 41 (15.1%) who had four seg-
ments with clinically significant disease, and
137 (50.4%) who had five or more segments
with clinically significant disease.
Overall, 4,003 iliofemoral segments were
considered in the field of view on digital sub-
traction angiography. Of these, 2,962 (74.0%)
segments were considered to be without signif-
icant disease, whereas 983 (24.6% segments
were considered to have significant disease
(597 [14.9%] segments with significant
(≥ 51%) stenosis, 386 [9.6%] segments with
occlusions). The remaining 58 (1.4%) segments
were considered to be technically inadequate.
The diagnostic performance of MR an-
giography for the detection of significant ste-
noocclusive disease of the iliofemoral arteries
using digital subtraction angiography as the
reference standard is summarized in Table 2.
All off-site reviewers and on-site investiga-
tors obtained significantly (p < 0.001) higher
sensitivity, specificity, and overall accuracy
for the detection of significant stenoocclusive
disease for CE-MRA compared with TOF
MRA. After eliminating the possibility of
within-cluster correlation effect, the results of
the GEE model analysis confirmed the signif-
icantly better sensitivity (odds ratio [OR], 4.3
[95% CI, 3.4–5.5]) and specificity (OR, 3.6
[2.7–4.8]) of CE-MRA compared with TOF
MRA. Overall increases in accuracy of
17.0% (15.5–18.5%), 15.9% (14.2–17.5%),
and 9.9% (8.5–11.3%) were determined for
off-site reviewers 1, 2, and 3, respectively,
whereas a greater increase in accuracy of
26.1% (24.4–27.8%) was determined for the
on-site investigators. Examples of the im-
proved image quality achievable on CE-MRA
with 0.1 mmol/kg of gadobenate dimeglumine
compared with TOF MRA and of the excellent
correlation of gadobenate dimeglumine–en-
hanced MR angiography and digital subtrac-
tion angiography are shown in Figures 1–4.
A significant (p < 0.00001) increase in
agreement among the three MR angiography
reviewers was noted for the CE-MRA image
sets (82% agreement; κ, 0.66) compared with
the TOF MRA image sets (65.2% agreement;
κ, 0.45) (Table 3).
Determinations of PPV, NPV, positive like-
lihood ratio, and negative likelihood ratio con-
firmed the better performance for CE-MRA
compared with TOF MRA for both off-site
reviewers and on-site investigators (Table 4).
Calf arteries—CE-MRA of the calf arteries
was performed for 263 (91.6%) of the 287
participants who underwent CE-MRA of the
iliofemoral arteries. Conversely, only 141
(49.1%) participants underwent TOF MRA of
the calf arteries. Digital subtraction angiogra-
phy correlation was available for 241 (91.6%)
of the 263 participants who underwent CE-
MRA of the calf arteries.
A total of 1,507 calf artery segments were
considered to be in the field of view on digital
subtraction angiography. Significant stenooc-
clusive disease was noted in 465 (30.9%) of
these 1,507 segments (150 [10.0%] segments
with significant (≥ 51%) stenosis, 315
[20.9%] segments with occlusions), whereas
889 (59.0%) of 1,507 segments were consid-
ered to be without significant disease. The re-
maining 153 (10.2%) segments were consid-
ered technically inadequate.
The diagnostic performance of MR an-
giography for the detection of significant ste-
noocclusive disease of the calf arteries rela-
tive to digital subtraction angiography is
summarized in Table 5. Although slightly
lower values for sensitivity, specificity, and
accuracy were obtained compared with val-
ues obtained for the iliofemoral arteries, sig-
nificantly better performance was noted in all
cases by each MR angiography reviewer for
CE-MRA compared with TOF MRA. Similar
trends to those observed in the iliofemoral ar-
teries were also noted for PPV, NPV, positive
likelihood ratio, and negative likelihood ratio.
Collateral Circulation and Associated Disease
Collateral circulation was detected in a
greater percentage of stations on CE-MRA
(8.5–10.3% of the stations examined at MR
angiography and digital subtraction angiogra-
phy) compared with TOF MRA (3.7–4.0% of
the stations) across the three blinded MR an-
giography reviewers. A similar trend was
noted by on-site investigators (26.8% on CE-
MRA compared with 10.1% on TOF MRA).
Accuracy for the detection of collateral circu-
lation ranged from 82.0% to 89.0% for CE-
MRA and from 71.5% to 88.3% for TOF
MRA when compared with the collateral cir-
culation detected on digital subtraction an-
giography. The difference in accuracy be-
tween TOF MRA and CE-MRA for the
detection of collateral circulation was signif-
icant for MR angiography reviewer 3
(p = 0.027) and for the on-site investigators
(p < 0.001) but not for MR angiography re-
viewers 1 and 2.
TABLE 2: Sensitivity, Specificity, and Accuracy of TOF MRA and CE-MRA for Detection of Significant Stenoocclusive 
Disease of the Iliofemoral Arteries Using Digital Subtraction Angiography as the Reference Standard
Performance
Measure
Reviewer 1 Reviewer 2 Reviewer 3 On-Site Reviewer
TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA
Sensitivity
(%)
33.2
(314/945)
54.0a
(527/976)
62.8
(590/940)
80.9a
(786/971)
42.0
(389/926)
67.4a
(657/975)
39.9
(359/900)
61.6a
(552/896)
Specificity
(%)
79.4
(2,273/2,862)
95.3a
(2,809/2,947)
74.3
(2,096/2,820)
89.7a
(2,619/2,920)
88.9
(2,504/2,817)
94.0a
(2,763/2,940)
59.4
(1,853/3,119)
86.9a
(2,719/3,128)
Accuracy
(%)
68.0
(2,587/3,807)
85.0a
(3,336/3,923)
71.4
(2,686/3,760)
87.5a
(3,405/3,891)
77.3
(2,893/3,743)
87.4a
(3,420/3,915)
55.0
(2,212/4,019)
81.3a
(3,271/4,024)
Note—TOF MRA = time-of-flight MR angiography, CE-MRA = contrast-enhanced MR angiography.
aStatistically significant increase from TOF MRA (p < 0.001 based on McNemar test).
Thurnher et al.
1228 AJR:189, November 2007
Blinded evaluation of digital subtraction an-
giography images revealed associated disease
in 172 (4.4%) of 3,945 iliofemoral segments
(aneurysm in 45 [1.1%] segments and associ-
ated disease classified as “other” in 127 [3.2%]
segments). In 3,773 (95.6%) segments, no as-
sociated disease was present. The three blinded
MR angiography reviewers detected associ-
ated aneurysms in 43 (1.1%), 22 (0.6%), and
34 (0.9%) segments, respectively, on CE-
MRA and in three (0.1%), 18 (0.5%), and eight
(0.2%) segments, respectively, on TOF MRA.
No associated disease was recorded for
98.3–98.8% of segments on CE-MRA and
99.2–99.7% of segments on TOF MRA.
Safety
A total of 43 nonserious adverse events were
reported by 30 (10.5%) of 287 participants
overall, of which 32 events in 22 (7.7%) partic-
ipants were considered of probable, possible,
unknown, or missing relationship to the admin-
istration of gadobenate dimeglumine. The re-
maining events were considered unrelated. All
events were either mild (87%) or moderate
(13%) in intensity, and no serious adverse
events were reported. The most commonly re-
ported events that were considered of potential
relationship to the administration of gado-
benate dimeglumine were injection site warmth
Fig. 1—52-year-old man with 
Leriche syndrome.
A and B, Contrast-enhanced 
MR angiography (CE-MRA) with 
0.1 mmol/kg of gadobenate 
dimeglumine displays entire 
peripheral runoff vasculature to 
calf arteries. Short segment 
occlusion of right common iliac 
artery and high-grade stenosis 
of left common iliac artery are 
evident (arrows, B).
C, Unenhanced time-of-flight 
MR angiography shows 
occlusion of both common iliac 
arteries and suggests 
segmental occlusion of calf 
arteries. However, image 
quality is compromised by 
venous overlay.
D, Digital subtraction 
angiography confirms findings 
of CE-MRA examination.
A
B
CD
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Fig. 2—54-year-old man with mild upper right leg claudication.
A–C, Contrast-enhanced MR angiography (CE-MRA) with 0.1 mmol/kg of gadobenate dimeglumine displays entire 
peripheral runoff vasculature to calf arteries. Moderate stenoses are apparent in right common iliac artery (arrow, 
B) and right superficial femoral artery (arrow, C).
D and E, Unenhanced time-of-flight MR angiography overestimates extent of stenosis in right common iliac artery 
(arrow, D) and underestimates stenosis in right superficial femoral artery (arrow, E).
(Fig. 2 continues on next page)
D
E
w
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(1.7%, 5/287), increased systolic blood pres-
sure (1.4%, 4/287), increased diastolic blood
pressure (1.0%, 3/287), and nausea (0.7%,
2/287). All increases in blood pressure reported
as adverse events were recorded in one partici-
pant at one site. No other event was reported by
F
G
Fig. 2 (continued)—54-year-old man with mild upper 
right leg claudication.
F and G, Digital subtraction angiography confirms 
findings of CE-MRA examination: Moderate stenoses 
are apparent in right common iliac artery (arrow, F) and 
right superficial femoral artery (arrow, G).
A
B
C
Fig. 3—59-year-old man with moderate to severe upper left leg claudication.
A–C, Contrast-enhanced MR angiography (CE-MRA) with 0.1 mmol/kg of gadobenate dimeglumine reveals 
aneurysm, high-grade stenosis of left common iliac artery (arrow, B), and high-grade stenosis of left superficial 
femoral artery (arrow, C).
(Fig. 3 continues on next page)
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D F
Fig. 3 (continued)—59-year-old man with moderate to 
severe upper left leg claudication.
D and E, Unenhanced time-of-flight MR angiography 
(TOF MRA) fails to adequately show vascular disease 
in left common iliac artery because of artifacts caused 
by turbulent flow (arrow, D). High-grade stenosis in left 
superficial femoral artery is underestimated on TOF 
MRA (arrow, E).
F and G, Digital subtraction angiography confirms 
findings of CE-MRA examination: Note aneurysm, high-
grade stenosis of left common iliac artery (arrow, F), 
and high-grade stenosis of left superficial femoral 
artery (arrow, G).
E G
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A B
Fig. 4—66-year-old man with diabetes.
A, Contrast-enhanced MR angiography (CE-MRA) with 0.1 mmol/kg of gadobenate dimeglumine reveals severe 
stenosis (arrow) of left popliteal artery. In addition, bilateral occlusion of posterior tibial artery and segmental 
stenoses of anterior tibial artery and tibiofibular trunk are apparent.
B, Digital subtraction angiography confirms high-grade stenosis (arrow) of left popliteal artery and arterial disease 
of calf arteries.
more than one participant. No clinically mean-
ingful time-related changes were noted for vital
signs or clinical laboratory investigations, and
no significant effects were noted for any cardiac
electrophysiology parameter.
Discussion
Appropriate management of patients with
suspected peripheral arterial occlusive disease
depends on accurately differentiating patients
with clinically relevant stenoocclusive disease
who typically require some form of therapeutic
intervention from participants without clini-
cally relevant disease for whom a more conser-
vative approach to treatment is generally pre-
ferred. Usually stenoocclusive disease resulting
in vessel lumen narrowing of ≥ 51% is consid-
ered the threshold for defining patients for
whom therapeutic intervention should be con-
sidered. Accordingly, our study was performed
predominantly in patients with moderate to
severe peripheral arterial occlusive disease
(232/287 [80.8%] patients with stage IIb–IV
disease according to the staging of disease by
Fontaine et al. [33]) because these patients are
the population most likely to undergo routine
CE-MRA of the peripheral vasculature.
Although our primary objective was to as-
sess the diagnostic performance of CE-MRA
with 0.1 mmol/kg of gadobenate dimeglumine
relative to conventional digital subtraction an-
giography, additional comparison with unen-
hanced TOF MRA was performed to meet
guidelines issued by the U.S. Food and Drug
Administration (FDA) [34] and the Committee
for Proprietary Medicinal Products (CPMP)
[35] concerning the development of diagnostic
imaging agents. However, because the unac-
ceptably long acquisition times of TOF MRA
sequences precluded successful unenhanced
TOF imaging of the entire runoff vasculature
including the calf station in a large number of
patients (only approximately half the patients
underwent TOF MRA of the calf arteries, and
many could not lie still in the bore of the
magnet for the entire acquisition time of the
sequence), the primary focus of our study
was the iliofemoral vasculature, comprising
the aortoiliac and femoropopliteal stations.
As was to be expected on the basis of find-
ings from previous comparisons of CE-MRA
TABLE 3: Interobserver Agreement 
for Determinations of 
Accuracy for TOF MRA and 
CE-MRA Using Digital 
Subtraction Angiography as 
the Reference Standard
Agreement
No. (%) of Segments
TOF MRA CE-MRA
No. of segmentsa 3,968 4,202
All 3 reviewers agree 2,588 (65.2) 3,445 (82.0)
At least 2 of 3 
reviewers agree
3,848 (97.0) 4,180 (99.5)
κ 0.45 0.66
Note—TOF MRA = time-of-flight MR angiography, 
CE-MRA = contrast-enhanced MR angiography.
aIncludes all segments in field of view for all 
reviewers.
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TABLE 4: Positive and Negative Predictive Values and Likelihood Ratios for TOF MRA and CE-MRA Using Digital 
Subtraction Angiography as the Reference Standard
Performance
Measure
Reviewer 1 Reviewer 2 Reviewer 3 On-Site Reviewer
TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA
PPVa
(%)
34.8
(314/903)
79.2
(527/665)
44.9
(590/1,314)
72.3
(786/1,087)
55.4
(389/702)
78.8
(657/834)
22.1
(359/1,625)
57.4
(552/961)
NPVb
(%)
78.3
(2,273/2,904)
86.2
(2,809/3,258)
85.7
(2,096/2,446)
93.4
(2,619/2,804)
82.3
(2,504/3,041)
89.7
(2,763/3,081)
77.4
(1,853/2,394)
88.8
(2,719/3,063)
PLRc 1.6 11.5 2.4 7.9 3.8 11.2 1.0 4.7
NLRd 0.8 0.5 0.5 0.2 0.7 0.3 1.0 0.4
Note—TOF MRA = time-of-flight MR angiography, CE-MRA = contrast-enhanced MR angiography, PPV = positive predictive value, NPV = negative predictive value, PLR = 
positive likelihood ratio, NLR = negative likelihood ratio.
aNumber of correctly identified diseased (≥ 51%) segments / total number of segments considered positive.
bNumber of correctly identified nondiseased (≤ 50%) segments / total number of segments considered negative.
cSensitivity / (1 – specificity).
d(1 – sensitivity) / specificity.
TABLE 5: Diagnostic Performance of TOF MRA and CE-MRA in the Calf Arteries Using Digital Subtraction Angiography 
as the Reference Standard
Performance
Measure
Reviewer 1 Reviewer 2 Reviewer 3
TOF MRA CE-MRA TOF MRA CE-MRA TOF MRA CE-MRA
Sensitivity (%) 3.7 (4/107) 45.0a (157/349) 47.9 (45/94) 79.0a (282/357) 33.3 (32/96) 67.8a (248/366)
Specificity (%) 63.8 (187/293) 89.3a (625/700) 64.7 (163/252) 74.4a,b (539/724) 75.3 (198/263) 82.5a,c (586/710)
Accuracy (%) 47.8 (191/400) 74.5a (782/1,049) 60.1 (208/346) 75.9a (821/1,081) 64.1 (230/359) 77.5a (834/1,076)
PPVd (%) 3.6 (4/110) 67.7 (157/232) 33.6 (45/134) 60.4 (282/467) 33.0 (32/97) 66.7 (248/372)
NPVe (%) 64.5 (187/290) 76.5 (625/817) 76.9 (163/212) 87.8 (539/614) 75.6 (198/262) 83.2 (586/704)
PLRf 0.1 4.2 1.4 3.1 1.3 3.9
NLRg 1.5 0.6 0.8 0.3 0.9 0.4
Note—TOF MRA = time-of-flight MR angiography, CE-MRA = contrast-enhanced MR angiography, PPV = positive predictive value, NPV = negative predictive value, 
PLR = positive likelihood ratio, NLR = negative likelihood ratio.
aStatistically significant increase from TOF MRA (p < 0.001 based on McNemar test).
bStatistically significant increase from TOF MRA (p = 0.01).
cStatistically significant increase from TOF MRA (p = 0.024).
dNumber of correctly identified diseased (≥ 51%) segments / total number of segments considered positive.
eNumber of correctly identified nondiseased (≤ 50%) segments / total number of segments considered negative.
f Sensitivity / (1 – specificity).
g(1 – sensitivity) / specificity.
with unenhanced MR angiography [36–38],
CE-MRA of the iliofemoral arteries with
gadobenate dimeglumine was significantly
(p < 0.001) better than TOF MRA for all main
measures of diagnostic performance (i.e., sen-
sitivity, specificity, and accuracy for detection
of significant stenoocclusive disease). Each of
the three off-site blinded reviewers reported
values of ≥ 85% for the diagnostic accuracy of
CE-MRA for the detection of significant ste-
noocclusive disease of the iliofemoral arteries
compared with digital subtraction angiogra-
phy. These values compare favorably with val-
ues reported elsewhere for CE-MRA with
other gadolinium-based MR contrast agents [8,
9, 39] and imply that correct classification of
patients in terms of the need for interventional
treatment or conservative follow-up is achiev-
able in at least 85% of cases. Although the on-
site investigators reported a slightly lower
combined value for overall accuracy (81.3%),
these investigators, like the off-site reviewers,
were fully blinded to the results of the digital
subtraction angiography procedure.
Because of the artificial full-blinding con-
ditions of the off-site reviewers to all patient
clinical and radiologic information in this
study, a reduction of the diagnostic accuracy
by 10–15% might not be unexpected [40].
Notably, a recent study comparing the con-
ventional extracellular gadolinium contrast
agents gadodiamide and gadopentetate di-
meglumine for the detection of hemodynam-
ically relevant stenosis reported accuracy
values of 71–100% for the common iliac ar-
teries, 57–71% for the external iliac arteries,
and 12–50% for the internal iliac arteries
[41]. Moreover, two recent phase III clinical
trials performed to obtain regulatory approval
for gadofosveset for peripheral CE-MRA
determined diagnostic accuracy values of
83.8–90.3% [42] and 80.3–87.6% [43] for the
detection of significant aortoiliac occlusive
disease. Each of these studies was performed
using an MR angiography protocol design
similar to that used in our study, using similar
CE-MRA sequences and similar assessment
methodology involving fully blinded evalua-
tion of all MR angiography images by three
highly experienced independent reviewers.
Regarding other parameters of diagnostic
performance, whereas the values for specific-
ity (≥ 89.7% for all three off-site reviewers)
were in line with values reported elsewhere
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[8–12, 37, 39, 41–45], slightly lower values for
sensitivity (33.2–62.8% for TOF MRA,
54.0–80.9% for CE-MRA) were obtained. In
particular, the sensitivity for off-site reviewer 1
was lower than the values determined for the
other two reviewers. On the other hand, strong
interreviewer agreement for the diagnosis of
clinically significant stenoocclusive disease
was shown both for agreement between two re-
viewers and for agreement among all three re-
viewers. Specifically, all three blinded review-
ers agreed in 82% (κ = 0.66) of segment
evaluations on CE-MRA compared with just
65.2% (κ = 0.45) on TOF MRA. On the basis
of the guidelines provided by Landis and Koch
[46] for describing the clinical value of degree
of concordance, the kappa value obtained in
this study leads to the conclusion that gado-
benate dimeglumine–enhanced MR angiogra-
phy is a diagnostic test with substantial repro-
ducibility. Similar consensus among reviewers
was noted regarding the technical adequacy of
CE-MRA for visualization of the iliofemoral
arteries. For each off-site blinded reviewer, the
technical failure rate reported for CE-MRA
(2.5–3.4%) was significantly (p < 0.001) lower
than that reported for TOF MRA (6.2–18.0%)
and comparable to that reported for digital sub-
traction angiography (1.4%).
Because sensitivity and specificity may pro-
vide an incomplete picture of the clinical use-
fulness of MR angiography, additional assess-
ment was made of the PPV and NPV values.
Although the PPV indicates the actual likeli-
hood of disease in instances of a positive exam-
ination, the NPV indicates the likelihood of no
disease in instances of a negative examination.
The PPV determinations for the blinded re-
viewers in this study indicate that a positive il-
iofemoral segment on CE-MRA with gado-
benate dimeglumine is likely to be significant
stenoocclusive disease in approximately 80%
of cases. These results can be judged posi-
tively, especially considering the artificial en-
vironment in which they were obtained. The
NPV results (86.2–93.4%) indicate that the
risk of overlooking stenoocclusive disease on
CE-MRA with gadobenate dimeglumine is
low. Therefore, a normal study at CE-MRA
with gadobenate dimeglumine should obviate
further potentially hazardous conventional an-
giographic or surgical procedures.
Differently from predictive values and val-
ues for sensitivity and specificity, the values
for positive likelihood ratio and negative like-
lihood ratio are not affected by the prevalence
of disease [47]. Thus, determination of these
values offers an approach to assessing diag-
nostic performance that is unaffected by the
condition being evaluated in the population.
The positive likelihood ratio indicates the ef-
fect of a positive examination finding on the
probability that the condition in question ex-
ists, and the negative likelihood ratio ad-
dresses the effect of a negative examination
on the probability that the condition in ques-
tion is present. Likelihood ratio values there-
fore provide quantification of the effect of
MR angiography on diagnostic thinking—
that is, the impact of the MR angiography test
result on the a priori probability of clinically
significant stenoocclusive disease versus the a
posteriori probability of such disease [48]. A
positive likelihood ratio of ≥ 7.9 for each
blinded reviewer in this study suggests that a
positive finding on CE-MRA of the iliofemo-
ral arteries would in each case lead to a mod-
erate to large and often conclusive shift in the
probability of ≥ 51% stenoocclusive disease
being present. The PPV, NPV, and likelihood
ratios determined for CE-MRA were consis-
tently superior to those determined for TOF
MRA, thereby providing supplemental con-
firmation of the superiority of CE-MRA for
diagnostic imaging of the iliofemoral arteries.
Concerning the calf arteries, excellent visu-
alization has previously been shown with both
unenhanced MR angiography [49–51] and
CE-MRA [7, 11, 44, 52], although venous con-
tamination and reduced signal-to-noise ratio
(SNR) have sometimes been reported for the
latter approach [53, 54]. In this study, mark-
edly better diagnostic performance (sensitivity,
specificity, and accuracy) and favorable pre-
dictive values and likelihood ratios were noted
by all three off-site blinded reviewers for CE-
MRA of the calf arteries compared with TOF
MRA. As in the iliofemoral arteries, the tech-
nical failure rate determined by the off-site re-
viewers for CE-MRA of the calf arteries
(8.2–14.2%) was comparable to that of digital
subtraction angiography (10.2%). Although
the technical failure rate and overall accuracy
values (74.5–77.5%) for detection of signifi-
cant stenoocclusive disease of the calf arteries
were slightly inferior to those of the iliofemo-
ral arteries, the caliber of the calf vessels is
much smaller than that of the iliofemoral arter-
ies and the acquisition of good-quality images
is more technically challenging.
Although comparison of the diagnostic per-
formance of gadobenate dimeglumine with
that of other gadolinium agents was not per-
formed in this study, the calf arteries are one
vascular territory in which the greater relaxiv-
ity of gadobenate dimeglumine compared with
that of other agents [21–23] is likely to prove
beneficial in terms of vessel visualization and
diagnostic performance. In this regard, previ-
ous studies [27, 28] have shown that the con-
trast enhancement (SNR and contrast-to-noise
ratio) and visualization of below-the-knee seg-
ments is significantly better after the adminis-
tration of 0.1 mmol/kg of gadobenate dimeglu-
mine compared with an equivalent dose of
gadopentetate dimeglumine [27], and that ga-
dobenate dimeglumine may have a significant
beneficial effect on the ability to assess below-
the-knee segments [28].
Specifically, a study by Wyttenbach et al.
[28] not only showed better diagnostic perfor-
mance for gadobenate dimeglumine com-
pared with gadoterate meglumine at an equiv-
alent dose but also noted significantly fewer
nonassessable below-the-knee segments after
gadobenate dimeglumine. Wyttenbach et al.
administered a standard volume of 34 mL of
either gadobenate dimeglumine or gadoterate
meglumine to all patients. Given that both
agents are formulated at concentrations of 0.5
mol/L [22], this volume equates to an admin-
istered dose of almost 0.25 mmol/kg of body
weight for an average 70-kg person. Although
this dose may be appropriate in the case of ga-
doterate meglumine and other conventional
gadolinium agents [12, 45, 55] with standard
r1 relaxivity [21, 22], previous studies have
shown that doses of gadobenate dimeglumine
of 0.2 mmol/kg of body weight have at best
minimal and at worst slightly deleterious ef-
fects on overall CE-MRA image quality [56,
57]. Studies performed in vitro have sup-
ported these clinical observations in showing
that the r1 relaxivity of gadobenate dimeglu-
mine is concentration-dependent, with higher
relaxivity values, and hence greater signal in-
tensity enhancement, at lower concentrations
[58]. Possibly Wyttenbach et al. might have
obtained even better results for peripheral
CE-MRA with gadobenate dimeglumine had
just a single 0.1 mmol/kg dose been used.
A single 0.1 mmol/kg dose of gadobenate
dimeglumine has previously been shown to
be equivalent to a double dose of a conven-
tional gadolinium agent (gadopentetate
dimeglumine) for CE-MRA of the renal ar-
teries [26] and superior to a double dose of
this agent for CE-MRA of the carotid arter-
ies [25], with particular benefits noted for
the visualization of small or narrow vessels.
Given the current widespread concern
among the radiology community about the
use of double and triple doses of gadolinium
contrast agents, particularly in patients with
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renal insufficiency who may be at risk of
nephrogenic systemic fibrosis [59, 60], our
results with just a single 0.1 mmol/kg dose
of gadobenate dimeglumine might be of
considerable additional interest, especially
given the relatively favorable physicochem-
ical properties of this agent compared with
other agents [58, 61]. Furthermore, part
(4–5%) of the injected dose of gadobenate
dimeglumine is eliminated by the hepatobil-
iary system [62], and a reduced 0.1 mmol/kg
dose may result in potential cost savings.
A principal limitation of our study inherent
to its multicenter design is the range of MRI
systems and sequence parameters used. More-
over, because innovative technology such as
parallel imaging [63] and time-resolved MR
angiography [38] were in their infancy and
not widely available at the time the study was
planned and conducted, and because most of
the 26 investigational centers did not have ac-
cess to state-of-the-art MRI systems, the
study was performed using conventional MR
angiography technology appropriate to the re-
spective imaging capabilities of the individ-
ual centers. Both image quality and diagnos-
tic performance might have improved had this
more advanced technology been available.
Because gadobenate dimeglumine has a
higher r1 relaxivity and boosts intravascular
signal more than other available extracellular
gadolinium agents [24–28], it may prove use-
ful in conjunction with parallel imaging,
which penalizes SNR, especially in vascular
territories such as the peripheral arteries, for
which increased spatial resolution or speed is
beneficial. Further investigation of this effect
may be of interest in the future.
In conclusion, our study shows that CE-
MRA of the lower extremities with gado-
benate dimeglumine is significantly more ef-
ficacious than TOF MRA, and that CE-MRA
is an appropriate alternative to invasive digital
subtraction angiography for the diagnostic
evaluation of the pelvic and lower leg vascu-
lature in patients with known or suspected pe-
ripheral arterial occlusive disease. Moreover,
the administration of gadobenate dimeglu-
mine was safe, and no clinically meaningful
effects on vital signs, clinical laboratory in-
vestigations, or cardiac electrophysiology pa-
rameters were observed.
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